Nifty: 4 stocks Jay Thakkar is bullish on from pharma sector
The momentum had definitely weakened out there, we did see some consolidation happening out there but there was no price correction as like that of Nifty and Bank Nifty.
Stay updated with breaking news from Pharma Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The momentum had definitely weakened out there, we did see some consolidation happening out there but there was no price correction as like that of Nifty and Bank Nifty.
There are 18 pharma-healthcare sector funds, including seven passively managed schemes, which manage assets worth Rs 15,240 crore as on June 30, 2023. Some of these schemes invest in healthcare stocks listed overseas. Are they offering good value?
The Pharmaceutical Contract Manufacturing Organization (CMO) Market size is estimated at USD 161.37 billion in 2023, and is expected to reach USD 210.50...
The index is likely to consolidate in the monthly F&O expiry week, and if the index takes support and rebounds, then 18,700-18,900 could be the resistance area, whereas 18,500-18,450 could be the next crucial support in case of correction in coming sessions
As investors await RBI monetary policy announcement and foreign investment. Choice Broking recommends buying Bajaj Finserv, Dr Reddy's, and SBI.